$1.84
-2.9%Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Chief Executive Officer & Chairman
Compensation
$62,195
Chief Financial Officer
Compensation
$255,645
General Counsel & Secretary
Vice President of Operations
During the last 12 months, insiders have purchased $67K worth of STXS shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
30.0K
66.60K
0
0.00
+67K
+$67K
0
0.00
0
0.00
+0
+$0
Isaac Paul J
Director, Other: See Remarks
$67K
No selling activity
Strong bullish signal with $67K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
STXS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | April 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 04, 2025 | April 04, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 05, 2023 | April 05, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 08, 2022 | April 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | April 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 09, 2020 | April 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 10, 2019 | April 09, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 12, 2018 | May 22, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 13, 2017 | May 23, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.